YKL-40 in patients with end-stage renal disease receiving haemodialysis.
Nielsen, Ture Lange; Plesner, Louis Lind; Warming, Peder Emil; Pallisgaard, Jannik Langtved; Dalsgaard, Morten; Schou, Morten; Høst, Ulla; Rydahl, Casper; Brandi, Lisbet; Køber, Lars; Johansen, Julia Sidenius; Kastrup, Jens; Iversen, Kasper Karmark.
; 23(4): 357-363, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29357700
Mortality prediction in stable hemodialysis patients is refined by YKL-40, a 40-kDa glycoprotein associated with inflammation.
Acid-Base and Electrolyte Managements in Chronic Kidney Disease and End-Stage Renal Disease: Case-Based Discussion.
The stability and variability of serum and plasma fibroblast growth factor-23 levels in a haemodialysis cohort.
Genetic and epigenetic regulation of YKL-40 in childhood.
CD62P and P10 as predictive markers for assessing the efficacy of hemodialysis in treating end-stage renal disease.
Ischemia-Modified Albumin Is Associated with Arterial Stiffness in Hemodialysis Patients.
Relationship between serum bilirubin levels and mortality in patients on peritoneal dialysis.
Functional sympatholysis is impaired in end-stage renal disease.
Association of plasma potassium with mortality and end-stage kidney disease in patients with chronic kidney disease under nephrologist care - The NephroTest study.
Change in Lactate Levels After Hemodialysis in Patients With End-Stage Renal Disease.